DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Pennsylvania Convention Center

2016 年 06 月 26 日 8:30 上午 - 2016 年 06 月 26 日 12:00 下午

1101 Arch Street, , Philadelphia, PA 19107 , USA

#22: Successful Drug Development: Best Practices for Clinical Trial Design, Agency Interactions, and Regulatory Document Writing

概览

An additional registration fee is required for all preconference tutorials. Register today for this tutorial.

Understanding best practices is critical as you design a clinical program and regulatory strategy for a drug or biologic product. Identifying and obtaining the data actually needed for a product development program is key to the success of the program. Thinking ahead to the marketing application helps a sponsor avoid many of the common mistakes that are made in designing individual clinical trials and overall drug development programs. Even though it may be years before an NDA/BLA/MAA submission, the marketing application is the goal of each development program and should be kept in view throughout the program to avoid pitfalls and delays in submission and product approval.

This tutorial will cover common mistakes and solutions in the areas of drug development planning, clinical study design, statistical analysis planning, regulatory agency interactions, and regulatory document writing. Practical advice for each of these areas will be presented, with an emphasis on learning from past examples and case studies that illustrate approaches to adopt or to avoid.

谁应该参加?

This tutorial is designed for professionals with basic knowledge in regulatory affairs, agency submissions, and regulatory medical writing.

学习目标

  • Identify ways to increase the efficiency and success of product development programs;
  • Describe key principles for successful regulatory interactions during drug development and marketing application preparation;
  • Discuss best practices in developing successful clinical trial designs, statistical analysis plans, and regulatory submission documents.

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。